BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31702003)

  • 21. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence.
    Arévalo-Lorido JC; Gómez JC; Huelgas RG; de Lucas DG; Polo LM; Aguilar JMV; Muñoz JE
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):417-420. PubMed ID: 30251110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiologist as a cardiometabolic specialist.
    Katsi V; Andrikou I; Tsioufis C; Tousoulis D
    J Clin Hypertens (Greenwich); 2019 Sep; 21(9):1432-1435. PubMed ID: 31355513
    [No Abstract]   [Full Text] [Related]  

  • 24. New anti-diabetic agents: major advances with unanswered questions.
    Sabouret P; Bocchino PP; Biondi-Zoccai G
    Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center.
    Hamid A; Vaduganathan M; Oshunbade AA; Ayyalasomayajula KK; Kalogeropoulos AP; Lien LF; Shafi T; Hall ME; Butler J
    J Cardiovasc Pharmacol; 2020 Sep; 76(3):313-320. PubMed ID: 32569016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
    Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
    Testani JM; Inzucchi SE; Voors AA
    Circulation; 2019 May; 139(21):2383-2385. PubMed ID: 31107618
    [No Abstract]   [Full Text] [Related]  

  • 28. New Therapeutic Strategies for Type 2 Diabetes
    Yehya A; Sadhu AR
    Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory.
    Bonora E; Cataudella S; Marchesini G; Miccoli R; Vaccaro O; Fadini GP; Martini N; Rossi E
    Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):1945-1953. PubMed ID: 32998821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Which person with diabetes should receive cardioprotective glucose-lowering medicines?
    Bloomgarden ZT
    J Diabetes; 2020 May; 12(5):352-353. PubMed ID: 32119186
    [No Abstract]   [Full Text] [Related]  

  • 32. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
    Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
    Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
    Fadini GP; Frison V; Simioni N; Lapolla A; Gatti A; Bossi AC; Del Buono A; Fornengo P; Gottardo L; Laudato M; Perseghin G; Bonora E; Avogaro A
    J Am Heart Assoc; 2019 Jul; 8(14):e012244. PubMed ID: 31269877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.
    Gao Y; Peterson E; Pagidipati N
    Am Heart J; 2020 Jun; 224():47-53. PubMed ID: 32304879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Human Factor: The Cost of Switching from Analog to Human Insulin.
    Tsai A
    Diabetes Forecast; 2017 Mar; 70(2):44-47. PubMed ID: 29897684
    [No Abstract]   [Full Text] [Related]  

  • 36. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A New Algorithm Dedicated to Blood Glucose Monitoring in Insulin-Treated Elderly Dependent People With Diabetes.
    Grino M; Loundou A; Boucekine M; Alitta Q; Oliver C
    J Diabetes Sci Technol; 2019 Mar; 13(2):410-412. PubMed ID: 30537870
    [No Abstract]   [Full Text] [Related]  

  • 38. Understanding drug preferences, different perspectives.
    Mol PG; Arnardottir AH; Straus SM; de Graeff PA; Haaijer-Ruskamp FM; Quik EH; Krabbe PF; Denig P
    Br J Clin Pharmacol; 2015 Jun; 79(6):978-87. PubMed ID: 25469876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Admission fasting plasma glucose is associated with in-hospital outcomes in patients with acute coronary syndrome and diabetes: findings from the improving Care for Cardiovascular Disease in China - Acute Coronary Syndrome (CCC-ACS) project.
    Ye N; Yang L; Wang G; Bian W; Xu F; Ma C; Zhao D; Liu J; Hao Y; Liu J; Yang N; Cheng H;
    BMC Cardiovasc Disord; 2020 Aug; 20(1):380. PubMed ID: 32819275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.